Pressure ulcers are an unmet medical need
Pressure ulcers are skin wounds that develop when prolonged pressure restricts blood flow at points where the body contacts a surface, most often a hospital bed. These ulcers can progress rapidly, are often infected, and require medical intervention. Untreated pressure ulcers may require advanced wound care and cause the patient to become septic.
Pressure ulcers are defined as a “never event” in healthcare settings, which means that the treatment of any ulcer acquired during a patient’s hospitalization is not eligible for reimbursement. As such, hospitals take measures to prevent them entirely. Never events also trigger facility quality reviews and increase liability.
>2.5 million
new pressure ulcer cases occur in the United States alone every year
70%
of new diagnoses are early stage where prevention of progression is more effective
$26.8B
is the estimated cost of care for hospital-acquired pressure injuries
First-in-class solution for pressure ulcers
CTX-005 is a topical gel formulation intended to be applied directly to the skin daily to help prevent the formation and reduce the risk of progression of pressure ulcers. The product is classified as a medical device.
Preclinical Research Findings
A comprehensive preclinical program has assessed the efficacy of CTX-005 in preventing the progression of pressure ulcers. CTX-005 improves skin strength, preserves tissue integrity, and supresses inflammatory pathways that drive ulcer formation and progression. The product has been shown to outperform the standard of care.
Prevention of Pressure Ulcers
CTX-005 reduces formation of PUs by increasing skin collagen content, enhancing structural integrity, and preserving skin thickness.
Reduction in Inflammation
CTX-005 significantly reduce inflammatory markers, mitigating the inflammatory response that contributes to tissue degradation.
Superior to Leading Product
CTX-005 outperforms Cavilon® cream and spray in reducing the rate and severity of PU progression.
Skin Regeneration and Protection
CTX-005 promotes collagen deposition, ensuring long-term durability and resilience of the skin under pressure.
Together, we can accelerate innovation and bring meaningful therapies to patients who need them most.
Ceria is in an exciting stage of growth as we advance our drug candidates toward key development milestones. We welcome collaboration and dialogue with those interested in supporting our mission — whether through investment, strategic partnership, or scientific engagement.
To learn more or explore opportunities to get involved, contact our team at info@ceriatx.com.
Ceria Therapeutics
Tucson, AZ | San Juan, PR